CareDx Inc (NASDAQ: CDNA) stock soared over 6% in pre-market trading on Thursday, following the company's impressive fourth-quarter 2024 financial results. The surge can be attributed to CareDx's robust performance, with the company reporting a 32% year-over-year increase in quarterly revenue to $86.6 million and achieving adjusted EBITDA of $9.8 million.
The healthcare company, which specializes in precision medicine solutions for transplant patients, has been capitalizing on strong demand for its testing services. This segment saw a 37% year-over-year growth, driven by a 14% increase in test volumes. Additionally, CareDx significantly expanded its payer coverage, adding millions of new commercially covered lives for its products.
CareDx's solid performance was further bolstered by its robust financial position, as the company ended 2024 with a strong cash balance of $261 million and no debt. This financial strength positions CareDx well for future growth initiatives and potential strategic opportunities.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。